Artificial Life (ALIF) announces second healthcare iPhone/iPad app

Artificial Life, Inc.,  announced yesterday their upcoming mobile telemedicine health solution, NeuroDerMo, the second in a series of mobile healthcare products. The name "NeuroDerMo" is short for Neurodermatitis + Mobile. Neurodermatitis is a serious skin condition that will be monitored and managed by the application through inputs by patients and caregivers.

Research shows that six percent of the world's population is suffering from some form of neurodermatitis and that its prevalence globally is on the rise*. This skin disorder may be associated with other medical conditions such as psychological disorders, depression anxiety, nervousness eczema and/or psoriasis. It can also be exacerbated by chronic scratching and is common in children*.

NeuroDerMo is launched as a management solution for this segment of the population suffering from neurodermatitis and can be used as an aid in the successful treatment of the condition. This product leverages Artificial Life 's (ALIF) OPUS-M™ platform for end-consumers, healthcare providers and healthcare businesses. NeuroDerMo is scheduled for commercial availability in early Q2 2011. The product follows the Company's successful launch of their first healthcare monitoring mobile application GluCoMo™, a diabetes monitoring mobile application on the iPhone and iPad.

Introducing NeuroDerMo

The NeuroDerMo app is a mobile telemedicine and healthcare solution allowing patients, caregivers, doctors, and hospitals to share and communicate through mobile mediums such as smartphones, tablets, netbooks and other mobile internet devices. The goal is to track changes in skin conditions by closely monitoring many variables (such as redness, itchiness, etc.) which is facilitated by mobile data sharing and smart back-end processes. The NeruoDerMo app will enable remote and real-time monitoring and management of patients by doctors and hospitals with enhanced healthcare services which can result in a reduction in administration costs. NeuroDerMo offers an easily accessible repository of monitoring data for the neurodermatitis condition for patients to share with friends, families and caregivers.

NeruoDerMo has a customized mobile device front-end client and portal as well as a custom back-end infrastructure supported by Artificial Life's m-commerce solution OPUS-M™:

Front-end
The NeuroDerMo front-end is comprised of two parts, a mobile client and a web portal. The mobile client is able to support most major smartphone platforms; allowing users to keep track of relevant information in real time such as wound condition tracking, food and medication intake and more. A photo diary with camera snapshots of affected areas gives users a chronological visual diary of their condition history. Sharing of information is also simplified and promoted through online social communities and forums so that users can quickly share their latest medical status, wound conditions, and other medical information with others. For greater flexibility and convenience, a synchronized web portal is also available for users and their friends, family members, and caregivers.

Back-end
The NeuroDerMo back-end is powered by Artificial Life's OPUS-M™ technology and allows for friends, families, and caregivers to share critical information with each other.

Business Model
The front-end mobile client of NeuroDerMo will initially be launched as a free mobile app and service with limited features. Depending on the needs of the users, additional premium features and functions for the mobile client can then be purchased inside the mobile app in the coming versions.

NeuroDerMo will soon also be offered as a white label solution and can be adopted by doctors, health clinics, hospitals and/or healthcare industry businesses. The pricing of the customization, integration and maintenance services are based on monthly rental and usage fees.

"Artificial Life further expands its telemedicine health app portfolio with our upcoming launch of NeuroDerMo, a powerful mobile monitoring solution for patients suffering from neurodermatitis. We plan to grow more in the telemedicine field and will soon expand our healthcare app portfolio to include a wide-ranging family of mobile monitoring apps available across many smartphone platforms," said Eberhard Schoneburg, CEO of Artificial Life, Inc.


POSITION: LONG